Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...
Medpage Today on MSN14d
Novel Drug Improved Symptoms in Eosinophilic Esophagitis
The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in ...
6abc News8d
Recognizing EOE, a digestive disorder probably triggered by an allergic reaction
Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...
Business Insider15h
Eupraxia reports data from RESOLVE Phase 1b/2a trial
Eupraxia Pharmaceuticals (EPRX)announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic ...
Medscape8d
Eosinophilic Esophagitis: the newest esophageal inflammatory disease
Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...
Hosted on MSN5d
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...
The Globe and Mail15d
Eosinophilic Esophagitis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Currently the product is in Phase III stage of development for the treatment of Eosinophilic Esophagitis. IRL201104, is uniquely safe and efficacious demonstrating immunoregulatory activity in a ...
Pharmabiz6d
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...
PharmiWeb6d
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the approval covers children aged one to ...
Daily5d
Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis
Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...
Medscape9d
Eosinophilic Esophagitis: the newest esophageal inflammatory disease
Nat Clin Pract Gastroenterol Hepatol. 2009;6(5):267-278. A thorough history and assessment of allergic diseases is a vital part of the evaluation of a patient with suspected EoE because of the ...
Morningstar7d
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Executive Vice President, Head of Research and Development, Sanofi “Up to half of all children in the EU with eosinophilic esophagitis remain uncontrolled despite existing standard of care ...